阵发性房颤进展的患病率与决定因素
本研究为Reappraisal of AF研究的中期分析,纳入417例阵发性房颤患者,基线全面表型分析并随访≥1年连续节律监测。房颤进展定义为进展为持续性/永久性房颤或负荷增加>3%,发生率为5.5%/年。多变量分析识别出PR间期、左房功能受损、二尖瓣反流和腰围与房颤进展相关,加入血液生物标志物后模型C统计量从0.709提升至0.830。
要点
- 阵发性房颤年进展率为5.5%/年。
- PR间期、左房功能受损、二尖瓣反流和腰围是房颤进展的预测因素。
- 加入生物标志物可提升预测模型区分度(C统计量0.709→0.830)。
核心结论
- 阵发性房颤患者房颤进展发生率为5.5%/年,预测因素包括心房重构标志物、性别、二尖瓣反流、腰围及凝血、炎症、心肌牵张和动脉粥样硬化相关生物标志物。
研究设计与样本
- Reappraisal of AF研究(NCT02726698)的中期分析,纳入417例阵发性房颤患者,基线全面表型分析并随访≥1年连续节律监测。
主要发现
- 平均年龄65(58-71)岁,179例(43%)为女性,随访2.2(1.6-2.8)年,51/417例(5.5%/年)出现房颤进展。
- 多变量分析显示PR间期、左房功能受损、二尖瓣反流和腰围与房颤进展相关。
- 加入血液生物标志物后模型C统计量从0.709提升至0.830,男性、较低因子XIIa:C1-酯酶抑制剂和组织因子途径抑制物水平、较高NT-proBNP、PCSK9和肽聚糖识别蛋白1水平与房颤进展相关。
关键数值与推荐
- 房颤进展定义为进展为持续性或永久性房颤,或阵发性房颤负荷增加>3%。
临床怎么用
- 预测模型可能有助于确定房颤进展风险和治疗靶点,但需外部验证。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Atrial fibrillation (AF) often progresses from paroxysmal AF (PAF) to more permanent forms. To improve personalised medicine, we aim to develop a new AF progression risk prediction model in patients with PAF. METHODS: In this interim-analysis of the Reappraisal of AF: Interaction Between HyperCoagulability, Electrical Remodelling, and Vascular Destabilisation in the Progression of AF study, patients with PAF undergoing extensive phenotyping at baseline and continuous rhythm monitoring during follow-up of ≥1 year were analysed. AF progression was defined as (1) progression to persistent or permanent AF or (2) progression of PAF with >3% burden increase. Multivariable analysis was done to identify predictors of AF progression. RESULTS: Mean age was 65 (58-71) years, 179 (43%) were female. Follow-up was 2.2 (1.6-2.8) years, 51 of 417 patients (5.5%/year) showed AF progression. Multivariable analysis identified, PR interval, impaired left atrial function, mitral valve regurgitation and waist circumference to be associated with AF progression. Adding blood biomarkers improved the model (C-statistic from 0.709 to 0.830) and showed male sex, lower levels of factor XIIa:C1-esterase inhibitor and tissue factor pathway inhibitor, and higher levels of N-terminal pro-brain natriuretic peptide, proprotein convertase subtilisin/kexin type 9 and peptidoglycan recognition protein 1 were associated with AF progression. CONCLUSION: In patients with PAF, AF progression occurred in 5.5%/year. Predictors for progression included markers for atrial remodelling, sex, mitral valve regurgitation, waist circumference and biomarkers associated with coagulation, inflammation, cardiomyocyte stretch and atherosclerosis. These prediction models may help to determine risk of AF progression and treatment targets, but validation is needed. TRIAL REGISTRATION NUMBER: NCT02726698.
引用
- Nguyen BO, Weberndorfer V, Crijns HJ, et al. Prevalence and determinants of atrial fibrillation progression in paroxysmal atrial fibrillation. Heart. 2022. PMID: 35858774. doi:10.1136/heartjnl-2022-321027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。